Advertisement
New Zealand markets closed

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NZD/USD

    0.5942
    +0.0006 (+0.10%)
     

  • NZD/EUR

    0.5547
    +0.0001 (+0.02%)
     

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • OIL

    82.88
    +0.07 (+0.08%)
     

  • GOLD

    2,325.60
    -12.80 (-0.55%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • Hang Seng

    17,295.93
    +94.66 (+0.55%)
     

  • NIKKEI 225

    37,672.46
    -787.62 (-2.05%)
     

  • NZD/JPY

    92.3550
    +0.2400 (+0.26%)
     

Immunovant to Present at the H.C. Wainwright Global Investment Conference on May 25th

Immunovant
·1-min read
Immunovant
Immunovant

NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference, taking place May 23rd-26th, 2022.

H.C. Wainwright Global Investment Conference fireside chat details:

Date:

Wednesday, May 25th, 2022

 

 

Time:

12:30 pm Eastern Time

 

 

Webcast:

The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com.

About Immunovant, Inc. 

Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, we are boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. Our investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). For additional information on the Company, please visit www.immunovant.com.

Contact:

Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
info@immunovant.com